{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T17:02:35Z","timestamp":1789578155580,"version":"build-2803163510"},"reference-count":38,"publisher":"The Endocrine Society","issue":"5","license":[{"start":{"date-parts":[[2021,2,9]],"date-time":"2021-02-09T00:00:00Z","timestamp":1612828800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"SUS fonder and Lundgrens stiftelse"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,4,23]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Context\/objective<\/jats:title>\n                  <jats:p>The aim of this study was to examine the effect of statins and other lipid-lowering agents on the development of Graves orbitopathy (GO) in patients with newly diagnosed Graves disease (GD).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Our sample included the full adult population of individuals living in Sweden with newly diagnosed GD between 2005 and 2018 (n\u2005=\u200534 894). We compared the GO incidence in statin users (n\u2005=\u20055574) and nonusers (n\u2005=\u200534 409) by applying Cox regression with a time-varying exposure variable. We adjusted for age, sex, and treatment for hyperthyroidism in the multivariate analyses.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Periods of nonusage lasted for a median of 4.3 years (interquartile range [IQR] 1.2-8.4), whereas periods of usage lasted for a median of 4.7 years (IQR 2.0-8.1). Among statin users, 77.1% had used simvastatin, 28.9% atorvastatin, and 8.2% had used other statins. Statin users were found to be significantly less likely to develop GO. In the main analysis based on the full cohort, the unadjusted hazard ratio (HR) was 0.74 (CI 0.65-0.84, P\u2005&amp;lt;\u2005.001), whereas full adjustment altered the effect to 0.87 (CI 0.76-1.00, P\u2005=\u2005.04). The main results were largely driven by men; the fully adjusted HR was 0.78 (CI 0.58-1.04, P\u2005=\u2005.09) for men and 0.91 (CI 0.79-1.06, P\u2005=\u2005.24) for women. Lipid-lowering agents other than statins did not exhibit a similar protective effect.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>In newly diagnosed patients with GD, treatment with statins may protect against the development of GO. Statins should be investigated in a clinical trial as a preventive treatment for GO in newly diagnosed patients with GD.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1210\/clinem\/dgab070","type":"journal-article","created":{"date-parts":[[2021,2,10]],"date-time":"2021-02-10T04:37:43Z","timestamp":1612931863000},"page":"1325-1332","source":"Crossref","is-referenced-by-count":76,"title":["Statins Decrease the Risk of Orbitopathy in Newly Diagnosed Patients with Graves Disease"],"prefix":"10.1210","volume":"106","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5774-7189","authenticated-orcid":false,"given":"Anton","family":"Nilsson","sequence":"first","affiliation":[{"name":"EPI@LUND, Division of Occupational and Environmental Medicine, Lund University, Lund, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kleoniki","family":"Tsoumani","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Sk\u00e5ne University Hospital, Malm\u00f6, Sweden"},{"name":"Department of Clinical Sciences Malm\u00f6, Lund University, Lund, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1398-5067","authenticated-orcid":false,"given":"Tereza","family":"Planck","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Sk\u00e5ne University Hospital, Malm\u00f6, Sweden"},{"name":"Department of Clinical Sciences Malm\u00f6, Lund University, Lund, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2021,2,9]]},"reference":[{"issue":"10","key":"2021122205021015100_CIT0001","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1055\/s-0035-1555762","article-title":"Current insights into the pathogenesis of Graves\u2019 ophthalmopathy","volume":"47","author":"Bahn","year":"2015","journal-title":"Horm Metab Res."},{"issue":"10","key":"2021122205021015100_CIT0002","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1089\/105072502761016476","article-title":"Epidemiology and prevention of Graves\u2019 ophthalmopathy","volume":"12","author":"Wiersinga","year":"2002","journal-title":"Thyroid."},{"issue":"3","key":"2021122205021015100_CIT0003","first-page":"998","article-title":"Thyrotropin receptor expression in Graves\u2019 orbital adipose\/connective tissues: potential autoantigen in Graves\u2019 ophthalmopathy","volume":"83","author":"Bahn","year":"1998","journal-title":"J Clin Endocrinol Metab."},{"issue":"1","key":"2021122205021015100_CIT0004","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1210\/er.2018-00066","article-title":"Insulin-like growth factor-I receptor and thyroid-associated ophthalmopathy","volume":"40","author":"Smith","year":"2019","journal-title":"Endocr Rev."},{"issue":"12","key":"2021122205021015100_CIT0005","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1007\/s40618-020-01341-2","article-title":"Putative protective role of autoantibodies against the insulin-like growth factor-1 receptor in Graves\u2019 disease: results of a pilot study","volume":"43","author":"Lanzolla","year":"2020","journal-title":"J Endocrinol Invest."},{"issue":"4","key":"2021122205021015100_CIT0006","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/s40618-018-0943-8","article-title":"Serum antibodies against the insulin-like growth factor-1 receptor (IGF-1R) in Graves\u2019 disease and Graves\u2019 orbitopathy","volume":"42","author":"Marin\u00f2","year":"2019","journal-title":"J Endocrinol Invest."},{"issue":"4","key":"2021122205021015100_CIT0007","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1056\/NEJMoa1910434","article-title":"Teprotumumab for the treatment of active thyroid eye disease","volume":"382","author":"Douglas","year":"2020","journal-title":"N Engl J Med."},{"issue":"18","key":"2021122205021015100_CIT0008","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1056\/NEJMoa1614949","article-title":"Teprotumumab for thyroid-associated ophthalmopathy","volume":"376","author":"Smith","year":"2017","journal-title":"N Engl J Med."},{"issue":"3","key":"2021122205021015100_CIT0009","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.beem.2012.03.011","article-title":"Management plan and delivery of care in Graves\u2019 ophthalmopathy patients","volume":"26","author":"Yang","year":"2012","journal-title":"Best Pract Res Clin Endocrinol Metab."},{"issue":"4","key":"2021122205021015100_CIT0010","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/S2213-8587(18)30020-2","article-title":"Mycophenolate plus methylprednisolone versus methylprednisolone alone in active, moderate-to-severe Graves\u2019 orbitopathy (MINGO): a randomised, observer-masked, multicentre trial","volume":"6","author":"Kahaly","year":"2018","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"21","key":"2021122205021015100_CIT0011","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","article-title":"Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein","volume":"359","author":"Ridker","year":"2008","journal-title":"N Engl J Med."},{"issue":"19","key":"2021122205021015100_CIT0012","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1161\/01.CIR.0000100688.17280.E6","article-title":"Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: rationale and design of the JUPITER trial","volume":"108","author":"Ridker","year":"2003","journal-title":"Circulation."},{"issue":"9","key":"2021122205021015100_CIT0013","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1586\/erc.09.93","article-title":"Primary prevention of vascular events in patients with high levels of C-reactive protein: the JUPITER study","volume":"7","author":"Fonseca","year":"2009","journal-title":"Expert Rev Cardiovasc Ther."},{"issue":"4","key":"2021122205021015100_CIT0014","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1177\/1753944709337056","article-title":"The Jupiter study, CRP screening, and aggressive statin therapy-implications for the primary prevention of cardiovascular disease","volume":"3","author":"Kones","year":"2009","journal-title":"Ther Adv Cardiovasc Dis."},{"issue":"4","key":"2021122205021015100_CIT0015","first-page":"204","article-title":"C-reactive protein: how has JUPITER impacted clinical practice?","volume":"9","author":"Verma","year":"2009","journal-title":"Ochsner J."},{"issue":"6","key":"2021122205021015100_CIT0016","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1053\/ajkd.2002.33393","article-title":"Effects of simvastatin on high-sensitivity C-reactive protein and serum albumin in hemodialysis patients","volume":"39","author":"Chang","year":"2002","journal-title":"Am J Kidney Dis."},{"issue":"5","key":"2021122205021015100_CIT0017","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1517\/14728222.7.5.613","article-title":"Statins and their potential targets in multiple sclerosis therapy","volume":"7","author":"St\u00fcve","year":"2003","journal-title":"Expert Opin Ther Targets."},{"issue":"3","key":"2021122205021015100_CIT0018","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1097\/01.wco.0000073942.19076.d1","article-title":"Statins as potential therapeutic agents in neuroinflammatory disorders","volume":"16","author":"St\u00fcve","year":"2003","journal-title":"Curr Opin Neurol."},{"issue":"3","key":"2021122205021015100_CIT0019","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1586\/17476348.2.3.329","article-title":"Statins as emerging treatments for asthma and chronic obstructive pulmonary disease","volume":"2","author":"Walsh","year":"2008","journal-title":"Expert Rev Respir Med."},{"issue":"5","key":"2021122205021015100_CIT0020","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1111\/j.1365-2362.2010.02434.x","article-title":"Statin use in patients with asthma: a nationwide population-based study","volume":"41","author":"Huang","year":"2011","journal-title":"Eur J Clin Invest."},{"issue":"9426","key":"2021122205021015100_CIT0021","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1016\/S0140-6736(04)16449-0","article-title":"Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial","volume":"363","author":"McCarey","year":"2004","journal-title":"Lancet."},{"issue":"4","key":"2021122205021015100_CIT0022","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1177\/1479164109339966","article-title":"Anti-inflammatory effects of simvastatin on adipokines in type 2 diabetic patients with carotid atherosclerosis","volume":"6","author":"Hu","year":"2009","journal-title":"Diab Vasc Dis Res."},{"issue":"12","key":"2021122205021015100_CIT0023","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1038\/nrd1901","article-title":"Anti-inflammatory effects of statins: clinical evidence and basic mechanisms","volume":"4","author":"Jain","year":"2005","journal-title":"Nat Rev Drug Discov."},{"issue":"4","key":"2021122205021015100_CIT0024","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s11154-018-9478-8","article-title":"Statins, metformin, proprotein-convertase-subtilisin-kexin type-9 (PCSK9) inhibitors and sex hormones: Immunomodulatory properties?","volume":"19","author":"Koch","year":"2018","journal-title":"Rev Endocr Metab Disord."},{"issue":"3","key":"2021122205021015100_CIT0025","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1001\/jamaophthalmol.2014.5103","article-title":"Risk factors for developing thyroid-associated ophthalmopathy among individuals with Graves disease","volume":"133","author":"Stein","year":"2015","journal-title":"JAMA Ophthalmol."},{"issue":"3","key":"2021122205021015100_CIT0026","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1089\/thy.2017.0430","article-title":"High serum cholesterol is a novel risk factor for Graves\u2019 orbitopathy: results of a cross-sectional study","volume":"28","author":"Sabini","year":"2018","journal-title":"Thyroid."},{"issue":"12","key":"2021122205021015100_CIT0027","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1007\/s40618-018-0915-z","article-title":"Relationship between serum cholesterol and Graves\u2019 orbitopathy (GO): a confirmatory study","volume":"41","author":"Lanzolla","year":"2018","journal-title":"J Endocrinol Invest."},{"key":"2021122205021015100_CIT0028","author":"Marin\u00f2"},{"issue":"8","key":"2021122205021015100_CIT0029","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1007\/BF03350193","article-title":"Temporal relationship between onset of Graves\u2019 ophthalmopathy and onset of thyroidal Graves\u2019 disease","volume":"11","author":"Wiersinga","year":"1988","journal-title":"J Endocrinol Invest."},{"issue":"1","key":"2021122205021015100_CIT0030","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/S0002-9149(97)00298-1","article-title":"The rule of 5 and the rule of 7 in lipid-lowering by statin drugs","volume":"80","author":"Roberts","year":"1997","journal-title":"Am J Cardiol."},{"issue":"45","key":"2021122205021015100_CIT0031","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.15585\/mmwr.mm6845a2","article-title":"Tobacco product use and cessation indicators among adults\u2014United States, 2018","volume":"68","author":"Creamer","year":"2019","journal-title":"MMWR Morb Mortal Wkly Rep."},{"issue":"9976","key":"2021122205021015100_CIT0032","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/S0140-6736(14)61368-4","article-title":"Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174 000 participants in 27 randomised trials","volume":"385","author":"Fulcher","year":"2015","journal-title":"Lancet."},{"issue":"4","key":"2021122205021015100_CIT0033","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1111\/j.1365-2265.1993.tb00516.x","article-title":"Age and gender influence the severity of thyroid-associated ophthalmopathy: a study of 101 patients attending a combined thyroid-eye clinic","volume":"38","author":"Perros","year":"1993","journal-title":"Clin Endocrinol (Oxf)."},{"issue":"6","key":"2021122205021015100_CIT0034","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.berh.2010.10.001","article-title":"Rheumatoid arthritis","volume":"24","author":"Carmona","year":"2010","journal-title":"Best Pract Res Clin Rheumatol."},{"issue":"3","key":"2021122205021015100_CIT0035","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.autrev.2017.10.013","article-title":"The anti-inflammatory effects of statins on patients with rheumatoid arthritis: a systemic review and meta-analysis of 15 randomized controlled trials","volume":"17","author":"Li","year":"2018","journal-title":"Autoimmun Rev."},{"key":"2021122205021015100_CIT0036","doi-asserted-by":"crossref","first-page":"933","DOI":"10.3389\/fendo.2019.00933","article-title":"Cholesterol serum levels and use of statins in Graves\u2019 orbitopathy: a new starting point for the therapy","volume":"10","author":"Lanzolla","year":"2019","journal-title":"Front Endocrinol (Lausanne)."},{"issue":"3","key":"2021122205021015100_CIT0037","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1007\/s12020-015-0762-z","article-title":"Statin reduces orbitopathy risk in patients with Graves\u2019 disease by modulating apoptosis and autophagy activities","volume":"53","author":"Bifulco","year":"2016","journal-title":"Endocrine."},{"issue":"9","key":"2021122205021015100_CIT0038","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1530\/EC-19-0319","article-title":"Simvastatin downregulates adipogenesis in 3T3-L1 preadipocytes and orbital fibroblasts from Graves\u2019 ophthalmopathy patients","volume":"8","author":"Shahida","year":"2019","journal-title":"Endocr Connect."}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgab070\/36447008\/dgab070.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/106\/5\/1325\/41848096\/dgab070.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/106\/5\/1325\/41848096\/dgab070.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,22]],"date-time":"2021-12-22T05:02:53Z","timestamp":1640149373000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/106\/5\/1325\/6131732"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,9]]},"references-count":38,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2021,2,9]]},"published-print":{"date-parts":[[2021,4,23]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgab070","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,5,1]]},"published":{"date-parts":[[2021,2,9]]}}}